ARTICLE | Company News
Five Prime, Inhibrx in GITR antibody deal
July 17, 2015 1:31 AM UTC
Five Prime Therapeutics Inc. (NASDAQ:FPRX) obtained exclusive, worldwide rights from Inhibrx LLC (La Jolla, Calif.) to its preclinical glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18) antibody program.
Inhibrx President and CEO Mark Lappe said the deal includes lead candidate INBRX-110, a mAb designed to activate GITR independent of Fc binding. Lappe declined to discuss potential indications, but said the GITR program has "very broad" potential in cancer. ...